Designation supported by promising safety and efficacy data from Phase 1/2 study in heavily pretreated patients with relapsed/refractory (R/R) chronic lymphocytic leukemia or small lymphocytic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback